Less Survivable Cancers

Peter Prinsley Excerpts

Tuesday 6th January 2026 Westminster Hall

[Peter Prinsley (Bury St Edmunds and Stowmarket) (Lab)]

It is a pleasure to serve under your chairship, Mr Efford. I thank the hon. Member for Wokingham (Clive Jones) for securing this debate. Cancer remains a most feared word. We doctors have learned to use all sorts of other words: “growths”, “tumours” and suchlike. There are relatives who will tell us, “Don’t use that word in front of the patient, for it would simply kill him.” But things have changed. Cancers that were considered incurable are now curable, and cancers for which there was no treatment are now treatable. Such is the power of scientific progress, for it is upon science that we will depend.

What exactly is a less survivable cancer? It is one defined by persistently poor outcomes across all stages. Many have mentioned the six with a survival rate at five years of only 16%. One such example was my lovely neighbour, who presented last Christmas with loss of vision in one eye. He was found to have secondary lung cancer in the retina. It was completely incurable and unamenable to any effective treatment. Sadly, he was dead within a few weeks.

Our country has a proud record of medical research. After all, it was here that we first discovered the link between cigarettes and lung cancer, when epidemiological studies of British doctors were conducted in the 1960s. When that was revealed, my own dad gave up his pipe. The greatest act of our new Government, some 60 years later, was to continue with the legislation introduced by the last Government to ban cigarette sales, eventually, for every citizen.

Clinical academics are doctors who not only teach the next generation of doctors, but translate scientific research into clinical applications and the supervision of clinical trials. I did an MD at the University of East Anglia on the clinical observation on the genetics of a rare ear disorder, so I understand the difficulties of medical research, but also the intrinsic delight that comes with unravelling the mysteries of medicine. That role is particularly critical for less survivable cancers, where progress will depend on sustained academic leadership on converting research into viable treatment.

Unfortunately, there has been a serious collapse in the number of clinical academics in our country. Many are now approaching retirement, and the levels of recruitment of young clinical academics are completely insufficient. We must address this crisis, starting with co-ordination between the Department of Health and Social Care and the Department for Education, so that salary equivalence is restored to retain the existing workforce on which our medical science depends. Let us do something we can actually do to make survivable cancer survivable. This is our political task.